Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: Report from the population-based Swedish CML registry

Blood

Volumn 122, Issue 7, 2013, Pages 1284-1292

  Höglund, Martin ^a   Sandin, Fredrik ^b   Hellström, Karin ^b   Björeman, Mats ^c   Björkholm, Magnus ^d   Brune, Mats ^e   Dreimane, Arta ^f   Ekblom, Marja ^g   Lehmann, Sören ^d   Ljungman, Per ^d   Malm, Claes ^f   Markevärn, Berit ^h   Myhr Eriksson, Kristina ⁱ   Ohm, Lotta ^d   Olsson Strömberg, Ulla ^a   Själander, Anders ^j   Wadenvik, Hans ^e   Simonsson, Bengt ^a   Stenke, Leif ^d   Richter, Johan ^g  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Regional Cancer Register   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁱ Lulea Hospital   (Sweden)

^j UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; SWEDEN; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; DRUG ANTAGONISM; MIDDLE AGED; MORTALITY; PROGNOSIS; REGISTER; SEX DIFFERENCE; STATISTICS; SURVIVAL RATE; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; REGISTRIES; SEX FACTORS; SURVIVAL RATE; SWEDEN; YOUNG ADULT;

EID: 84886776435     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-495598     Document Type: Article

References (38)

1. Björkholm M., Ohm L, Eloranta S., et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011; 29(18): 2514-2520.
2. de Lavallade H., Apperley JF, Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26(20): 3358-3363.
3. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a singleinstitution historical experience. Blood. 2012; 119(9): 1981-1987.
4. Wiggins CL, Harlan LC, Nelson H.E., et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med. 2010; 123(8): 764.e1-764.e9.
5. Hasford J, Pfirrmann M, Hehlmann R., et al.; Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90(11): 850-858. (Pubitemid 28280552)
6. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984; 63(4): 789-799. (Pubitemid 14141296)
7. Hasford J, Baccarani M, Hoffmann V., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011; 118(3): 686-692.
8. Jabbour E, Cortes J, Nazha A., et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012; 119(19): 4524-4526.
9. Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol. 2011; 29(29): 3944-3945.
10. Faber E, Mužík J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry. Eur J Haematol. 2011; 87(2): 157-168.
11. Lucas CM, Wang L, Austin G.M., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008; 22(10): 1963-1966.
12. Pulte D, Gondos A, Redaniel M.T., Brenner H. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011; 16(5): 663-671.
13. Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O., Höglund M; Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012; 119(17): 3890-3899.
14. Carlhed R, Bojestig M, Wallentin L., Lindström G, Peterson A., Aberg C, Lindahl B; QUICC study group. Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J. 2006; 152(6): 1175-1181. (Pubitemid 44854807)
15. Juliusson G, Antunovic P, Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009; 113(18): 4179-4187.
16. Höglund M., Björeman M, Björkholm M, et al. Real world data on chronic myeloid leukaemia: A report from the Swedish population based registry [abstract]. Haematologica. 2010; 95(337 Suppl 2). Abstract 0807.
17. Barlow L, Westergren K, Holmberg L., Talbäck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009; 48(1): 27-33.
18. Baccarani M, Saglio G, Goldman J., et al.; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108(6): 1809-1820. (Pubitemid 44394987)
19. Kaplan E. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958; 53(282): 457-481.
20. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101-121.
21. Dickman PW, Sloggett A, Hills M., Hakulinen T. Regression models for relative survival. Stat Med. 2004; 23(1): 51-64. (Pubitemid 38072106)
22. R Core Team R.C. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012.
23. StataCorp. Stata Statistical Software: Release, 11. College Station, TX: StataCorp LP; 2009.
24. http://www.sfhem.se/riktlinjer. KML nationella riktlinjer. 2010.
25. Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2010; 58(21): 1-40.
26. Bhayat F, Das-Gupta E, Smith C., McKeever T, Hubbard R. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009; 9: 252.
27. Cortes J, Silver R, Kantarjian H. Cancer Network. Cancer Management, 14th edition. Chronic Myeloid Leukemia (http://www.cancernetwork.com/cancer- management/chronic-myeloid-leukemia/article/10165/1802798). November 10, 2011. Accessed April 15, 2013.
28. Rohrbacher M, Berger U, Hochhaus A., et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009; 23(3): 602-604.
29. Socialstyrelsen. Cancer Incidence in Sweden 1997. http://www. socialstyrelsen.se/publikationer1999/1999-42-8. Accessed April 15, 2013.
30. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007; 121(10): 2260-2266. (Pubitemid 47585607)
31. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6): 1054-1061.
32. Breccia M, Tiribelli M, Alimena G. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol. 2012; 84(1): 93-100.
33. Shah BK, Ghimire KB. Chronic myeloid leukemia survival in older population in the United States [published online ahead of print March 8, 2013]. Leuk Lymphoma.
34. Baccarani M, Cortes J, Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35): 6041-6051.
35. Neelakantan P, Gerrard G, Lucas C., et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013; 121(14): 2739-2742.
36. O'Brien S.G., Guilhot F, Larson R.A., et al.; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11): 994-1004. (Pubitemid 36302244)
37. Regionalt Cancercentrum Uppsala Örebro. Rapport nr 5. Redovisning av material 2002-2010. http://www.cancercentrum.se/sv/uppsalaorebro/vardprocesser/ blodcancer/KML/vardprogram-register/. Accessed April 15, 2013.
38. Aarts MJ, Lemmens VE, Louwman M.W., Kunst AE, Coebergh JW. Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer. 2010; 46(15): 2681-2695.